The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes

Gonna, Hanney; Ray, Kausik K.

doi:10.1111/dom.13691

Cited by 17 publications

(16 citation statements)

References 126 publications

(217 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dyslipidemia is described as an abnormal level of circulating lipids. It has been acknowledged that dyslipidaemia increases the risk of cardiovascular disease development [ 69 ]. This condition may be of primary cause (genetic) or secondary (diet, drugs, chronic diseases, and metabolic disorders, including MetS).…”

Section: Ca Vs Dyslipidemiamentioning

confidence: 99%

Caffeic Acid on Metabolic Syndrome: A Review

et al. 2021

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a constellation of risk factors that may lead to a more sinister disease. Raised blood pressure, dyslipidemia in the form of elevated triglycerides and lowered high-density lipoprotein cholesterol, raised fasting glucose, and central obesity are the risk factors that could lead to full-blown diabetes, heart disease, and many others. With increasing sedentary lifestyles, coupled with the current COVID-19 pandemic, the numbers of people affected with MetS will be expected to grow in the coming years. While keeping these factors checked with the polypharmacy available currently, there is no single strategy that can halt or minimize the effect of MetS to patients. This opens the door for a more natural way of controlling the disease. Caffeic acid (CA) is a phytonutrient belonging to the flavonoids that can be found in abundance in plants, fruits, and vegetables. CA possesses a wide range of beneficial properties from antioxidant, immunomodulatory, antimicrobial, neuroprotective, antianxiolytic, antiproliferative, and anti-inflammatory activities. This review discusses the current discovery of the effect of CA against MetS.

show abstract

Section: Ca Vs Dyslipidemiamentioning

confidence: 99%

Caffeic Acid on Metabolic Syndrome: A Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The causal role of high cholesterol concentrations in the pathogenesis of chronic conditions is well established. Obesity and insulin resistance are linked to alterations in the lipoprotein particle profile and this may influence type 2 diabetes and cardiovascular disease (CVD) risk [2][3][4]. Traditional lipid tests quantify the cholesterol or triglyceride content of lipoproteins, and the amount of cholesterol carried by lipoprotein particles is thought to be an important parameter for estimating disease risk [5].…”

Section: Introductionmentioning

confidence: 99%

Protective lifestyle behaviours and lipoprotein particle subclass profiles in a middle-to older-aged population

et al. 2020

View full text Add to dashboard Cite

Background and aims: Lipoprotein particle size is associated with increased atherosclerosis and cardiovascular disease risk. Certain lifestyle behaviours may be cardioprotective. We examined lipoprotein particle size and concentration relationships with a protective lifestyle behaviour (PLB) score. Methods: This was a cross-sectional analysis of 2045 middle-to older-aged adults. Lipoprotein particle subclass size and concentrations were determined using nuclear magnetic resonance spectroscopy. Five protective behaviours included never smoking, moderate alcohol intake, moderate to vigorous physical activity, a high-quality diet (upper 40% Dietary Approaches to Stop Hypertension score) and a normal body mass index (BMI) (18.5-24.9 kg/m 2 ). Linear and logistic regression analyses tested individual protective behaviour and PLB score associations with lipoprotein subclasses. Results: Individual behaviour associations varied according to lipoprotein subclass, with normal BMI showing the greatest number of significant relationships. Logistic regression analyses revealed that subjects with the fewest number of protective behaviours had 1.4-2.8 increased odds of having less favourable lipoprotein profiles defined as above or below median level lipoprotein particle subclass size or concentration. Following additional adjustment for BMI, significant trend relationships were observed between the PLB score and large and medium very low-density lipoprotein (p = 0.001 and p < 0.001), total and smaller low-density lipoprotein (LDL) concentrations (p = 0.008 and p < 0.001), LDL size (p = 0.003) and a lipoprotein insulin resistance score (p = 0.003). Conclusions: Results show a cumulative protective effect of healthy lifestyle behaviours against an unfavourable potentially pro-atherogenic lipoprotein profile in middle-to older-aged adults, highlighting the importance of lifestyle promotion in healthy ageing.

show abstract

“…This is characterised by elevated levels of TGs, TG-rich lipoproteins, small dense LDL particles, and reduced HDL levels. 13 Lipid modification to reduce CVD events Normally, most cholesterol is carried in low-density lipoprotein cholesterol (LDL-C) and there is a strong, graded, positive association between total and LDL-C, and the risk of CVD over a wide range of plasma cholesterol concentrations. 14,15 There is unequivocal evidence that reducing plasma LDL-C reduces CVD risk, and various trials and epidemiological studies, with and without statins, using angiographic or clinical endpoints, have confirmed that the reducing LDL-C is also key component in preventing CVD.…”

Section: Trends In Urology and Men's Healthmentioning

confidence: 99%

“…People with diabetes have a particularly atherogenic lipid profile (diabetic dyslipidaemia), which is a key contributor to the development of atherosclerosis. This is characterised by elevated levels of TGs, TG‐rich lipoproteins, small dense LDL particles, and reduced HDL levels 13 …”

Section: Diabetes and Cvdmentioning

confidence: 99%